Prospective, Double-blind, Randomized, Placebo-Controlled Phase III Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis ("ProDERM Study")

Trial Profile

Prospective, Double-blind, Randomized, Placebo-Controlled Phase III Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis ("ProDERM Study")

Recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs Immune globulin (Primary)
  • Indications Dermatomyositis
  • Focus Therapeutic Use
  • Acronyms ProDERM
  • Sponsors Octapharma
  • Most Recent Events

    • 06 Apr 2017 Status changed from not yet recruiting to recruiting.
    • 08 Aug 2016 Planned initiation date changed from 1 Sep 2016 to 1 Dec 2016.
    • 12 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top